Ota J, Fujita M, Nakamura H, Taguchi T
Dept. of Oncologic Surgery, Osaka University.
Gan To Kagaku Ryoho. 1988 Aug;15(8 Pt 2):2640-5.
Degradable starch microspheres (DSM) have a mean diameter of 45 micron and temporarily obstruct blood flow at the arteriolar (micro-circulatory) level. A new approach was attempted to improve the anticancer effect on non-resectable liver cancer with simultaneous administration of DSM and MMC (mitomycin C) or ADR (adriamycin) into hepatic artery. Three patients with primary liver cancer were treated with DSM (600-1200 mg) and ADR (20-60 mg), and five with metastatic liver cancer were treated with DSM and MMC (10-20 mg). The treatment was repeated two to ten times. Partial or minor responses were observed in 1 out of 3 cases of primary liver cancer and 3 out of 5 metastatic cases. Side effects of DSM were temporary and mild epigastric or chest pain, vomiting, fever, slight dyspnea, etc. A temporary change in the liver functional data (GOT, GPT) was noted in 3 patients. Selective intra-hepatic arterial chemo-embolization therapy with DSM would appear to be beneficial for the treatment of liver cancers with appropriate indications. Cases in which DSM and anticancer drugs were effected were presented in detail.
可降解淀粉微球（DSM）的平均直径为45微米，可在小动脉（微循环）水平暂时阻断血流。尝试了一种新方法，通过将DSM与丝裂霉素C（MMC）或阿霉素（ADR）同时注入肝动脉，以提高对不可切除肝癌的抗癌效果。3例原发性肝癌患者接受了DSM（600 - 1200毫克）和ADR（20 - 60毫克）治疗，5例转移性肝癌患者接受了DSM和MMC（10 - 20毫克）治疗。治疗重复2至10次。3例原发性肝癌患者中有1例、5例转移性肝癌患者中有3例观察到部分或轻微反应。DSM的副作用为暂时性且轻微的上腹部或胸痛、呕吐、发热、轻度呼吸困难等。3例患者的肝功能数据（谷草转氨酶、谷丙转氨酶）出现暂时性变化。用DSM进行选择性肝内动脉化疗栓塞治疗似乎对有适当适应证的肝癌治疗有益。详细介绍了DSM与抗癌药物联合应用的病例。
